Navigation Links
Probiotic Delivery Technology Awarded Third International Patent
Date:12/16/2008

REDMOND, Wash., Dec. 16 /PRNewswire/ -- The Australian Patent Office has issued Nutraceutix, Inc. a patent for BIO-tract. It is the third international patent, from many patents pending, that the technology has been awarded based on BIO-tract's ability to protect sensitive ingredients like probiotic organisms from stomach acid on their way to optimal release sites in the intestinal tract.

Steve Moger, President and CEO of Nutraceutix comments: "Many years ago, we recognized the need for an effective probiotic and nutraceutical delivery technology -- one that draws from proven pharmaceutical principals, but does so in a fashion that is economically feasible in the nutritional supplement marketplace. With BIO-tract, we have addressed this need."

In the case of probiotics, three critical barriers must be overcome to fully benefit the consumer.

    --  Survival of these beneficial, but fragile organisms through the
        manufacturing process
    --  Survival on the store shelf
    --  Safe passage through the harsh stomach acids that may denature the
        organisms

BIO-tract products incorporate proven processes and technologies to overcome these barriers.

How BIO-tract works

Once ingested, BIO-tract tablets form a protective layer, which shields probiotic organisms from the acidic conditions of the stomach. After passing from the stomach to the intestinal tract, the tablets release the organisms at optimal rates determined by formulation.

Broad applications for BIO-tract

Application of the BIO-tract delivery system is not limited to probiotics. It has been applied to many other ingredients that benefit from effective gastric acid protection, buffering, controlled release and once-daily dosing. Custom BIO-tract formulations allow the controlled release of active ingredients at rates ranging from just a few hours to all day long.

Nutraceutix celebrates 25 years of manufacturing excellence

Based in Redmond, Washington, Nutraceutix, Inc. is celebrating its 25th year of manufacturing excellence as a probiotics and nutritional supplements company. Nutraceutix supplies natural probiotic strains and incorporates patented LiveBac(R) shelf-life enhancements and a variety of delivery technologies into custom probiotic products for clients. Nutraceutix also custom formulates and contract manufactures premium controlled-release nutraceuticals that offer enhanced bioavailability, reduced side effects and improved dose compliance. Nutraceutix produces bulk probiotic powders, and manufactures capsules and advanced tablets in bulk or finished bottles in its NSF certified GMP contract manufacturing facility.


'/>"/>
SOURCE Nutraceutix
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
2. New Young Investigator Grants for Probiotics Research Announced
3. Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research
4. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
5. Main Street Gourmet Launches New Probiotic Muffins
6. Isabellas Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic
7. Turtle Island Soup Gets Souped Up with New Probiotic, GandenBC30
8. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
9. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
10. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
11. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):